Latest News

According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...

Subgroup analysis results from the DELLphi-301 study found that tarlatamab showed promising efficacy with favorable benefit-risk profile among patients with previously treated small-cell lung cancer, regardless of baseline brain metastases.

Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.

Based on results from the phase 3 DUO-E trial, the FDA has approved durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance for patients with primary advanced or recurrent mismatch repair deficient endometrial cancer.

According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.

Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.

Based on results from the LIBRETTO-001 and the LIBRETTO–121 studies, the FDA has approved selpercatinib for adult and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are...

Exploratory results from the phase 3 AEGAN study found that the addition of perioperative durvalumab to neoadjuvant chemotherapy improved efficacy with manageable safety among treatment-naive patients with resectable non-small cell lung...

According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.

According to results from a phase 2 study, adebrelimab plus chemotherapy and sequential thoracic radiotherapy demonstrated promising efficacy and safety among patients with extensive-stage small-cell lung cancer.